Novo Nordisk A/S (NYSE:NVO) Shares Sold by GUARDCAP ASSET MANAGEMENT Ltd

GUARDCAP ASSET MANAGEMENT Ltd trimmed its stake in Novo Nordisk A/S (NYSE:NVOFree Report) by 0.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 35,797 shares of the company’s stock after selling 329 shares during the quarter. Novo Nordisk A/S makes up 0.0% of GUARDCAP ASSET MANAGEMENT Ltd’s holdings, making the stock its 20th largest holding. GUARDCAP ASSET MANAGEMENT Ltd’s holdings in Novo Nordisk A/S were worth $3,703,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of NVO. Pacific Center for Financial Services raised its holdings in shares of Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the period. Bell Investment Advisors Inc boosted its position in shares of Novo Nordisk A/S by 79.9% in the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after buying an additional 127 shares during the period. CNB Bank purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at $26,000. Tyler Stone Wealth Management raised its position in Novo Nordisk A/S by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after buying an additional 146 shares during the period. Finally, West Paces Advisors Inc. lifted its stake in Novo Nordisk A/S by 100.0% in the 3rd quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock worth $27,000 after acquiring an additional 150 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.4 %

Novo Nordisk A/S stock traded up $0.48 during mid-day trading on Tuesday, hitting $132.89. 2,919,349 shares of the company’s stock were exchanged, compared to its average volume of 4,781,216. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28. The stock has a 50 day moving average of $127.78 and a two-hundred day moving average of $114.41. The stock has a market cap of $596.35 billion, a P/E ratio of 45.76, a P/E/G ratio of 2.00 and a beta of 0.43. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17.

Wall Street Analyst Weigh In

NVO has been the topic of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price for the company. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target on the stock. Finally, UBS Group began coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $133.60.

Check Out Our Latest Stock Analysis on Novo Nordisk A/S

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

See Also

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.